Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 2,800,000 shares, an increase of 77.2% from the March 15th total of 1,580,000 shares. Based on an average daily volume of 509,200 shares, the […]
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,800,000 shares, a growth of 77.2% from the March 15th total of 1,580,000 shares. Based on an average daily trading volume, of 509,200 shares, the short-interest ratio […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Compass Therapeutics (NASDAQ:CMPX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Earnings and Valuation This table compares Sutro Biopharma and […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent ratings […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price target trimmed by JMP Securities from $20.00 to $17.00 in a research note issued to investors on Monday, The Fly reports. The firm currently has an outperform rating on the stock. STRO has been the topic of several other research reports. Wedbush reissued an outperform rating […]